ADVISORY RESEARCH INC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 173 filers reported holding DENALI THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.6%.

Quarter-by-quarter ownership
ADVISORY RESEARCH INC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2020$974,000
+8.5%
27,185
-26.8%
0.10%
+18.8%
Q2 2020$898,000
+115.9%
37,136
+56.2%
0.08%
+175.9%
Q1 2020$416,00023,7760.03%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Crestline Management, LP 19,462,500$298,165,00048.02%
Bratton Capital Management, L.P. 953,035$14,600,00028.53%
Flagship Pioneering Inc. 8,005,747$122,648,0006.71%
Casdin Capital, LLC 650,000$9,958,000,0001.03%
Temasek Holdings (Private) Ltd 4,410,457$67,568,0000.50%
MARK ASSET MANAGEMENT LP 68,864$1,055,0000.26%
IRONWOOD INVESTMENT MANAGEMENT LLC 22,507$345,0000.26%
Artal Group S.A. 400,000$6,128,0000.25%
PIER 88 INVESTMENT PARTNERS LLC 40,610$622,0000.24%
HAMILTON LANE ADVISORS LLC 30,948$474,0000.20%
View complete list of DENALI THERAPEUTICS INC shareholders